Back to Results
First PageMeta Content
Chemistry / Amendments under the European Patent Convention / Disclaimer / Tamoxifen / European Patent Convention / Fulvestrant / Appeal procedure before the European Patent Office / Inventive step and non-obviousness / Aromatase inhibitor / European Patent Organisation / Civil law / Law


Document Date: 2013-06-06 17:04:05

Open Document

File Size: 148,49 KB

Share Result on Facebook

Company

Appeal Chambres / AstraZeneca AB / ASTRA ZENECA AB / APPEAL OF THE EUROPEAN PATENT OFFICE CHAMBRES DE RECOURS / BESCHWERDEKAMMERN / Appeal 3 / Teva Pharmaceutical Industries Ltd. / /

IndustryTerm

pharmaceutical formulations / treatment of resistant breast cancer / treatment of a patient with breast cancer / /

MedicalCondition

cancer / disease / breast cancer / Endocrine-Related Cancer / /

Organization

European Patent Office / Opposition Division / EPC / Technical Board of Appeal / European Patent Office Office / Environmental Protection Agency / /

Person

Michael Lederer / Qing Lu / U. Oswald A. Lindner / /

Position

Representative / Chairman / resistant breast cancer Patent Proprietor / /

ProgrammingLanguage

L / /

ProvinceOrState

Illinois / /

PublishedMedium

Breast Cancer Research and Treatment / /

Technology

detailed protocol / /

SocialTag